1. Strengthening Global Surveillance for Antimicrobial Drug–ResistantNeisseria gonorrhoeaethrough the Enhanced Gonococcal Antimicrobial Surveillance Program
- Author
-
John R. Papp, Emily J. Weston, and Teodora Wi
- Subjects
0301 basic medicine ,Sexually transmitted disease ,Epidemiology ,Gonorrhea ,lcsh:Medicine ,EGASP ,Global Health ,medicine.disease_cause ,0302 clinical medicine ,Euro-GASP ,antibiotic ,GRASP ,Global health ,AMR ,030212 general & internal medicine ,bacteria ,azithromycin ,urethral discharge ,gonococcal ,sexually transmitted disease ,Antimicrobial ,Strengthening Global Surveillance for Antimicrobial-Resistant Neisseria gonorrhoeae through the Enhanced Gonococcal Antimicrobial Surveillance Program (EGASP) ,Anti-Bacterial Agents ,Infectious Diseases ,Population Surveillance ,surveillance ,GISP ,Microbiology (medical) ,medicine.medical_specialty ,Surveillance Methods ,GLASS ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,Antibiotic resistance ,ciprofloxacin ,Environmental health ,Drug Resistance, Bacterial ,medicine ,Humans ,lcsh:RC109-216 ,antimicrobial resistance ,sexually transmitted infections ,global health security ,tetracycline ,business.industry ,Research ,Public health ,lcsh:R ,CARB ,medicine.disease ,Neisseria gonorrhoeae ,ceftriaxone ,penicillin ,030104 developmental biology ,antimicrobial ,quinolones ,AGSP ,business - Abstract
Monitoring trends in antimicrobial drug–resistant Neisseria gonorrhoeae is a critical public health and global health security activity because the number of antimicrobial drugs available to treat gonorrhea effectively is rapidly diminishing. Current global surveillance methods for antimicrobial drug–resistant N. gonorrhoeae have many limitations, especially in countries with the greatest burden of disease. The Enhanced Gonococcal Antimicrobial Surveillance Program is a collaboration between the World Health Organization and the Centers for Disease Control and Prevention. The program aims to monitor trends in antimicrobial drug susceptibilities in N. gonorrhoeae by using standardized sampling and laboratory protocols; to improve the quality, comparability, and timeliness of gonococcal antimicrobial drug resistance data across multiple countries; and to assess resistance patterns in key populations at highest risk for antimicrobial drug–resistant gonorrhea so country-specific treatment guidelines can be informed.
- Published
- 2017
- Full Text
- View/download PDF